Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 16;10:17578. doi: 10.1038/s41598-020-74592-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Linear model for the relationship of % change from baseline in coronary artery calcium (CAC) volume at week 52 versus average PD effect (%). Patients undergoing hemodialysis (N = 55) received placebo or SNF472 at doses of 300 or 600 mg/kg during dialysis, thrice weekly, for 52 weeks. Plasma crystallization inhibition was measured at the end of the infusion at weeks 1, 10, 22 and 52, and the average % inhibition of calcium phosphate crystallization found in these 4 sampling times was calculated and used in the model, as a read-out for the entire treatment of 52 weeks.